# A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06115135/  
OnCo record `nct06115135` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Venetoclax in multiple myeloma, run by Oncotherapeutics, now recruiting.

## Summary

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06115135 by Oncotherapeutics, with 39 participants planned, started 2024-06-20 and due to reach its primary completion in 2026-04-30. Interventions recorded: Venetoclax. Conditions listed: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06115135
- Phase: 2
- Setting: A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)
- Sponsor: Oncotherapeutics
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06115135: https://clinicaltrials.gov/study/NCT06115135

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct06115135.json